See the DrugPatentWatch profile for xgeva
Is Xgeva approved for osteoporosis?
No, Xgeva (denosumab) is not approved for osteoporosis. The FDA approves it for preventing skeletal-related events in patients with bone metastases from solid tumors and for treatment-induced bone loss in prostate or breast cancer patients on hormone therapy.[1] Osteoporosis treatment uses a different denosumab formulation, Prolia, given every six months at the same 60 mg dose.[1]
How does Xgeva differ from Prolia?
Xgeva and Prolia both contain denosumab, a RANKL inhibitor that slows bone breakdown, but they are distinct products with separate FDA approvals. Xgeva is dosed every four weeks at 120 mg for cancer-related bone issues, while Prolia treats postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and osteoporosis in men at higher fracture risk.[1][2] They cannot be interchanged due to different indications, dosing, and administration (both subcutaneous, but frequencies vary).[2]
Can Xgeva be used off-label for osteoporosis?
Off-label use occurs but lacks robust evidence and FDA support. Some clinicians prescribe Xgeva for osteoporosis in cases where Prolia is unavailable, citing similar mechanisms, though higher dosing raises hypocalcemia risks.[3] Guidelines from the American Society of Clinical Oncology and others do not endorse this; Prolia remains the standard.[3]
What are common side effects of Xgeva?
Side effects include hypocalcemia (low blood calcium), osteonecrosis of the jaw, atypical femoral fractures, and infections. Cancer patients on Xgeva report these at higher rates than osteoporosis patients on Prolia, partly due to dosing and comorbidities.[1][2] Dental checks are advised before starting.
When does Xgeva's patent expire?
Xgeva's key composition-of-matter patent (US 7,364,736) expires in 2025 in the US, with formulation patents extending protection into the early 2030s. Amgen faces biosimilar challenges; no approved biosimilars yet.[4]
Alternatives for osteoporosis treatment
Prolia leads denosumab options, alongside bisphosphonates like alendronate (Fosamax), zoledronic acid (Reclast), teriparatide (Forteo), romosozumab (Evenity), and abaloparatide (Tymlos). Choice depends on fracture risk, kidney function, and administration preference.[1]
[1]: FDA Label for Xgeva - https://www.accessdata.fda.gov/drugsatfdadocs/label/2010/125320s069lbl.pdf
[2]: FDA Label for Prolia - https://www.accessdata.fda.gov/drugsatfdadocs/label/2010/125320lbl.pdf
[3]: American Society of Clinical Oncology Guidelines - https://ascopubs.org/doi/full/10.1200/JCO.19.02706
[4]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/XGEVA